Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Key Highlights
- ➤Petrelintide cut body weight up to 10.7% at week 42 versus 1.7% placebo
- ➤Gastrointestinal adverse events were generally mild and similar to placebo
- ➤Waist circumference fell up to 10.8 cm versus 4.3 cm with placebo
- ➤Global Phase 3 ZUPREME registrational program has been initiated
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology * Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placebo * Treatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in pulse rate, high-sensitivity C-reactive protein and waist circumference * Additional results from the ZUPREME-1 study will be presented in an oral presentation at EASD 2026 on September 30 at 3:30pm CEST * A global Phase 3 ZUPREME registrational program with petrelintide monotherapy for chronic weight management has been initiated Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that results from its Phase 2 ZUPREME-1 trial evaluating investigational petrelintide have been published in The Lancet Diabetes & Endocrinology. The data will be presented at the 62(nd) Annual meeting of the European Association for the Study of Diabetes (EASD) 2026 on September 30, 2026, at 3:30pm CEST.
Get started
Create a free account to read the full story.